Regulatory compliance – Page 31

ERES controls not implemented during compliance audit – inspection evidence requirements

Managing ERES Controls Lapses During Compliance Audits: Your Playbook In an increasingly regulated environment, pharmaceutical manufacturers face mounting pressure to ensure robust compliance with Electronic Records and Electronic Signatures (ERES)…

Incomplete validation lifecycle during change control – risk-based validation alignment

Aligning the Validation Lifecycle with Change Control: A Practical Playbook In the pharmaceutical manufacturing world, ensuring a complete and compliant validation lifecycle during change control is paramount for maintaining product…

ERES controls not implemented during system operation – risk-based ERES remediation

Remediation for ERES Control Failures During System Operation In the evolving landscape of pharmaceutical manufacturing, the implementation of effective electronic records and electronic signatures (ERES) controls is critical. When ERES…

Change impact not assessed during system upgrades – risk-based validation alignment

Assessing Change Impact During System Upgrades: A Playbook for GMP Compliance In the dynamic landscape of pharmaceutical manufacturing, system upgrades are pivotal yet often overlooked for their potential impact on…

Archival process non-compliant during internal audit – evidence package inspectors expect

Addressing Non-Compliance in Archival Processes: A Playbook for Effective Internal Audits As pharmaceutical organizations strive to adhere to stringent regulatory standards, issues related to archival process compliance can pose significant…

System access controls weak during system upgrade – inspection evidence requirements

Strengthening System Access Controls During Upgrades: An Inspection-Ready Playbook Pharmaceutical manufacturers frequently confront challenges when upgrading electronic systems. A particularly critical issue arises when system access controls are weak during…

Incomplete validation lifecycle during lifecycle management – CAPA and revalidation strategy

Managing Incomplete Validation Lifecycles in Pharmaceutical Operations Incomplete validation lifecycles can pose significant risks to pharmaceutical manufacturing operations, leading to potential regulatory non-compliance and gaps in product quality assurance. This…

ERES controls not implemented during inspection walkthrough – risk-based ERES remediation

Handling Incomplete ERES Controls During Inspection Walkthroughs: A Comprehensive Playbook The pharmaceutical industry is under increasing scrutiny for the management of Electronic Records and Electronic Signatures (ERES). When ERES controls…

ERES controls not implemented during inspection walkthrough – risk-based ERES remediation

Risk-Based Remediation of ERES Controls Lapses During Inspection Walkthroughs In the pharmaceutical manufacturing realm, the integrity of electronic records and electronic signatures (ERES) is paramount. Encountering lapses in ERES controls…

Incomplete validation lifecycle during lifecycle management – preventing repeat validation findings

Preventing Repeated Validation Findings During Lifecycle Management The pharmaceutical manufacturing landscape increasingly faces challenges stemming from an incomplete validation lifecycle during lifecycle management. As regulatory scrutiny intensifies, organizations must address…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – 21 CFR Part 11 compliance gaps

Managing Hybrid Paper-Electronic Workflows: Tactics for Compliance During Inspections The increasing integration of hybrid paper-electronic workflows has created new challenges in regulatory compliance. Specifically, 21 CFR Part 11 requirements for…

Validation gaps identified during system upgrades – CAPA and revalidation strategy

Strategies for Addressing Validation Gaps During System Upgrades In pharmaceutical manufacturing, modernization is necessary to remain competitive and compliant. However, system upgrades can often reveal validation gaps that pose significant…